<DOC>
	<DOCNO>NCT02745496</DOCNO>
	<brief_summary>The clinical trial aim address critical challenge differentiate aggressive indolent prostate cancer correlate prospectively collect MultiParametric ( MP ) Magnetic Resonance Imaging ( MRI ) data ( index test ) histopathology radical prostatectomy specimen ( reference standard ) . The study design incorporate pre-biopsy MRI , routine standard care Transrectal Ultrasound guide ( TRUS ) biopsies MRI/Ultrasound ( US ) image fusion technique guide biopsy suspicious area identify MRI . The hypothesis MP-MRI allow pre-treatment determination prostate cancer aggressiveness MRI/US image fusion expect accurately co-locate cancer focus within prostate gland guide biopsy . Pre-treatment prediction Gleason grade marker cancer aggressiveness well inform clinicians patient improve risk stratification facilitate decision make subsequent treatment . Image fusion allow accurate target suspicious area MP-MRI biopsy , could obviate need multiple biopsy .</brief_summary>
	<brief_title>Advanced Magnetic Resonance Imaging ( MRI ) Men With Suspected Prostate Cancer</brief_title>
	<detailed_description>There preliminary evidence suggest MultiParametric Magnetic Resonance Imaging ( MP-MRI ) marker prostate cancer ( PCa ) aggressiveness could use plan treatment . Gleason grade ( GG ) critical predictor aggressiveness PCa , one three men , histology radical prostatectomy specimens different histology Transrectal Ultrasound ( TRUS ) -guided biopsy . This discrepancy contribute to- sign of- poor risk stratification men localise PCa . The research aim answer follow question : 1 . Can image-fusion technique allow investigator reliably target abnormal area see MP-MRI ? 2 . How reliable pre-biopsy MP-MRI correctly predict aggressive disease ? The investigator envisage MP-MRI information reduce unnecessary biopsy over-detection indolent PCa , improve detection aggressive disease . Primary Objectives • To determine whether use MP-MRI improve cancer detection characterisation Secondary Objectives • To determine whether US/MRI FUSON guide biopsy reduce number false negative biopsy need repeat biopsy</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Males age 4075 With least 10 year life expectancy ( defined American Society Anesthesiologists ( ASA ) physical status classification system ) Referred primary care With clinically localise PCa : Prostate Specific Antigen ( PSA ) &gt; 2.510 , 10.1 20 ng/ml And/or abnormal Digital Rectal Examination ( DRE ) &lt; T3 disease Unable give inform consent Prior prostatic biopsy Contraindications biopsy Poor general health life expectancy &lt; 10 year Previous diagnosis acute prostatitis Previous history prostatic surgery History prostate cancer Prior transurethral prostatectomy Contraindications MRI ( cardiac pacemaker , allergic reaction gadolinium base contrast , renal function baseline eGRF30ml/min , intracranial clip , claustrophobia ) Previous hip replacement</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Image-guided biopsy</keyword>
	<keyword>Tumour detection</keyword>
	<keyword>Diagnostic</keyword>
	<keyword>Biomarkers</keyword>
</DOC>